Title: Changes in liver stiffness values assessed using transient elastography in chronic hepatitis
B patients treated with tenofovir disoproxil fumarate: a prospective observational study
Version: 1 Date: 21 Oct 2022
Reviewer's report:
The current study aims to investigate the changes in LS values during the 144-week TDF
therapy in treatment-naïve CHB patients. A significant decline in LS was defined as #30%
decrease in LS value at week 96 from baseline. At week 96, 21 of 36 (58.3%) patients
showed a significant decline in LS value from baseline. A higher baseline LS value was
revealed to be a single independent predictor for the LS value reduction at week 96 from
baseline. A linear-regression prediction index was thereafter built to predict the LS value
at Week 96. The current study has been correctly implemented and the results are just
compatible with observations worldwide. Concerns: -Current interesting and correct observation
results have been commonly seen in research and review reports published over the past
years. -Introduction section should convey explicit yet concise, relevant published statement
and references. Please try addressing interesting and professional collections of the known
and unknown statements while the text proceeds to eventually addressing the study aims.
Oversimplification is noted; e.g., "Chronic hepatic inflammation during chronic infection of
hepatitis B virus (HBV) may lead to liver fibrosis.[3] " sounds incomplete and unprofessional
to hepatologists tackling longitudinal, serial or paired liver histology and LSMs over the past
decade. -On-treatment and off-treatment decline in LS values is an already and well-known fact.
Please try implementing other statistical methods including paired comparisons of values and
categories, generalized linear mixed modeling, whatever. However, the sample size is currently
too small to implement such approaches. -The current report would be a novel contribution
if kinetics of concurrent invaluable markers quantitated in liver histology, direct and indirect
fibrosis/necroinflammation biomarkers quantitated in blood sample, and novel LSM modalities
could be available longitudinally in the current small sample.
Title: Changes in liver stiffness values assessed using transient elastography in chronic hepatitis
B patients treated with tenofovir disoproxil fumarate: a prospective observational study
Version: 1 Date: 21 Oct 2022
Reviewer's report:
The current study aims to investigate the changes in LS values during the 144-week TDF
therapy in treatment-naïve CHB patients. A significant decline in LS was defined as #30%
decrease in LS value at week 96 from baseline. At week 96, 21 of 36 (58.3%) patients
showed a significant decline in LS value from baseline. A higher baseline LS value was
revealed to be a single independent predictor for the LS value reduction at week 96 from
baseline. A linear-regression prediction index was thereafter built to predict the LS value
at Week 96. The current study has been correctly implemented and the results are just
compatible with observations worldwide. Concerns: -Current interesting and correct observation
results have been commonly seen in research and review reports published over the past
years. -Introduction section should convey explicit yet concise, relevant published statement
and references. Please try addressing interesting and professional collections of the known
and unknown statements while the text proceeds to eventually addressing the study aims.
Oversimplification is noted; e.g., "Chronic hepatic inflammation during chronic infection of
hepatitis B virus (HBV) may lead to liver fibrosis.[3] " sounds incomplete and unprofessional
to hepatologists tackling longitudinal, serial or paired liver histology and LSMs over the past
decade. -On-treatment and off-treatment decline in LS values is an already and well-known fact.
Please try implementing other statistical methods including paired comparisons of values and
categories, generalized linear mixed modeling, whatever. However, the sample size is currently
too small to implement such approaches. -The current report would be a novel contribution
if kinetics of concurrent invaluable markers quantitated in liver histology, direct and indirect
fibrosis/necroinflammation biomarkers quantitated in blood sample, and novel LSM modalities
could be available longitudinally in the current small sample.
Please review this paper.
user
Title: Changes in liver stiffness values assessed using transient elastography in chronic hepatitis
B patients treated with tenofovir disoproxil fumarate: a prospective observational study
Version: 1 Date: 21 Oct 2022
Reviewer's report:
The current study aims to investigate the changes in LS values during the 144-week TDF
therapy in treatment-naïve CHB patients. A significant decline in LS was defined as #30%
decrease in LS value at week 96 from baseline. At week 96, 21 of 36 (58.3%) patients
showed a significant decline in LS value from baseline. A higher baseline LS value was
revealed to be a single independent predictor for the LS value reduction at week 96 from
baseline. A linear-regression prediction index was thereafter built to predict the LS value
at Week 96. The current study has been correctly implemented and the results are just
compatible with observations worldwide. Concerns: -Current interesting and correct observation
results have been commonly seen in research and review reports published over the past
years. -Introduction section should convey explicit yet concise, relevant published statement
and references. Please try addressing interesting and professional collections of the known
and unknown statements while the text proceeds to eventually addressing the study aims.
Oversimplification is noted; e.g., "Chronic hepatic inflammation during chronic infection of
hepatitis B virus (HBV) may lead to liver fibrosis.[3] " sounds incomplete and unprofessional
to hepatologists tackling longitudinal, serial or paired liver histology and LSMs over the past
decade. -On-treatment and off-treatment decline in LS values is an already and well-known fact.
Please try implementing other statistical methods including paired comparisons of values and
categories, generalized linear mixed modeling, whatever. However, the sample size is currently
too small to implement such approaches. -The current report would be a novel contribution
if kinetics of concurrent invaluable markers quantitated in liver histology, direct and indirect
fibrosis/necroinflammation biomarkers quantitated in blood sample, and novel LSM modalities
could be available longitudinally in the current small sample.
assistant